Aterian Inc vs Synopsys, Inc. — how do they compare? Aterian Inc trades at $0.47 (market cap $5.22M), while Synopsys, Inc. trades at $410 (market cap $78.83B). The key difference: Synopsys, Inc. is far larger — about 15101.5× Aterian Inc's market cap. Which is the better fit depends on your goals.
| ATER | SNPS | |
|---|---|---|
Market Cap | $5.22M | $78.83B |
Sector | Consumer Cyclical | Technology |
52-Week High | $1.39 | $625.80 |
52-Week Low | $0.36 | $372.33 |
Enterprise Value | $5.80M | $87.19B |
Signals from Pluang's Aura AI — not financial advice
Aterian (ATER) trades at $0.4934, up 7.03% in the last 24 hours, with a bearish technical signal overall. The company reported revenue of $68.98 million in 2025 but a net loss of $18.98 million, showing negative margins despite recent earnings beats. Recent news highlights a pending asset sale vote that could return $0.85–$1.14 per share to stockholders, creating near-term event-driven volatility.
The outlook hinges on the asset sale outcome, offering potential shareholder returns but also signaling business contraction. Risks include persistent cash burn, declining revenue, and high negative equity. Analysts are split 50/50 buy/hold, reflecting uncertainty amid restructuring efforts.
Synopsys (SNPS) trades at $415.99, up 2.47% with strong technical momentum near resistance at $419. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $3.35 vs. $3.15 expected) and revenue growth to $7.05B in 2025. Recent developments include strategic AI partnerships with AMD and Microsoft, positioning the company at the forefront of chip design innovation.
Outlook remains positive with analyst consensus target of $559.50 suggesting 34% upside, though high P/E of 95.19 and aggressive cash flow investments in 2025-2026 present valuation and execution risks. The stock's bullish technical setup and strong institutional support outweigh near-term concerns for long-term investors.
Trailing returns across standard periods
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →